Business
Prothena Announces Phase 2 PASADENA Study Results to be Presented at International Congress of Parkinson’s Disease and Movement Disorders
Phase 2 PASADENA Part 1 study results selected as an oral Top Abstract DUBLIN, Ireland, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc
About this update from Prothena Corporation Plc
[{"type":"text","content":"Phase 2 PASADENA Part 1 study results selected as an oral Top Abstract DUBLIN, Ireland, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced that results from Part 1 of the Phase 2 PASADENA study of prasinezumab in early Parkinson’s disease was selected as an oral Top Abstract presentation at the upcoming virtual International Congress of Parkinson’s Disease and Movement Disorders Society (MDS). Prasinezumab is the focus of a worldwide collaboration between Prothena and Roche. In addition, Wagner Zago, PhD, Prothena’s Chief Scientific Officer, will participate in a Science of Industry session during MDS.\n The PASADENA study results will be presented in the following oral Top Abstract session: Session 309: Update on Recent Clinical TrialsPASADENA: A Phase 2 study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease; Part 1 Week-52 resultsPresenter: Gennaro Pagano, MD, MSc, PhD, Senior Principal Medical Director, Translational Medicine, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Pharma Research and Early DevelopmentSession Launch Date and Time: Monday, September 14, 2020; 14:30 – 16:30 GMT; virtual congress sessions will remain available for a limited time after the launch date as an on-demand feature of the virtual congressA poster will also be included in the virtual poster hall during the virtual Congress In addition, Wagner Zago, PhD, Chief Scientific Officer, Prothena, will participate in the following session: Session 902: Immunotherapy for ProteinopathiesSession Launch Date and Time: Tuesday, September 15, 2020; 14:30 – 16:30 GMTSession type: Science of Industry (non-CME) About Prasinezumab Prasinezumab is a humanized monoclonal antibody under development for the potential treatment of Parkinson's disease. Prasinezumab targets alpha-synuclein and is designed to block the cell-to-cell transmission of the aggregated pathogenic forms of alpha-synuclein in Parkinson's disease, thereby slowing clinical decline. Prior to initiating clinical trials, the efficacy of prasinezumab was evaluated in various cellular and animal models of alpha-synuclein-related diseas...